 |
인쇄하기
취소
|
New anticancer medicine Jevtana designated as orphan drug
Sanofi-aventis Korea said that the Korea Food and Drug Administration has designated Jevtana (cabazitaxel) Injection as an orphan drug.
The company also said Jevtana is expected to be available as a marketed product within this year as a registration dossier of Jevtana is under regulatory review by the KFDA.
Jevtana, a microtubule inhibitor, in combination with prednisone was approved bas...
The company also said Jevtana is expected to be available as a marketed product within this year as a registration dossier of Jevtana is under regulatory review by the KFDA.
Jevtana, a microtubule inhibitor, in combination with prednisone was approved bas...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.